Pierfranco Conté

44.6k total citations · 9 hit papers
699 papers, 26.1k citations indexed

About

Pierfranco Conté is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Pierfranco Conté has authored 699 papers receiving a total of 26.1k indexed citations (citations by other indexed papers that have themselves been cited), including 495 papers in Oncology, 290 papers in Pulmonary and Respiratory Medicine and 204 papers in Cancer Research. Recurrent topics in Pierfranco Conté's work include Cancer Treatment and Pharmacology (194 papers), Breast Cancer Treatment Studies (152 papers) and HER2/EGFR in Cancer Research (152 papers). Pierfranco Conté is often cited by papers focused on Cancer Treatment and Pharmacology (194 papers), Breast Cancer Treatment Studies (152 papers) and HER2/EGFR in Cancer Research (152 papers). Pierfranco Conté collaborates with scholars based in Italy, United States and France. Pierfranco Conté's co-authors include Valentina Guarneri, Maria Vittoria Dieci, Suzette Delaloge, Norikazu Masuda, Binghe Xu, Nadine Tung, Elżbieta Senkus, Anne Armstrong, Mark E. Robson and Susan M. Domchek and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Pierfranco Conté

678 papers receiving 25.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine profile →
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

2000 1.7k citations Hans von der Maase, Steen Werner Hansen et al. Journal of Clinical Oncology profile →
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2019 1.6k citations Fabrice André, Eva Ciruelos et al. New England Journal of Medicine profile →
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

2005 1.2k citations Pierfranco Conté et al. profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations Kenichi Inoue, Norikazu Masuda et al. profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Mark E. Robson, Nadine Tung et al. profile →
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

2010 456 citations Pierfranco Conté, Giulia Bianchi et al. Journal of Clinical Oncology profile →
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

2020 371 citations Fabrice André, Eva Ciruelos et al. profile →
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

2022 130 citations Pierfranco Conté, Michelino De Laurentiis et al. ESMO Open profile →

Peers

Countries citing papers authored by Pierfranco Conté

Since Specialization

Citations

This map shows the geographic impact of Pierfranco Conté's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierfranco Conté with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierfranco Conté more than expected).

Fields of papers citing papers by Pierfranco Conté

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierfranco Conté. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierfranco Conté. The network helps show where Pierfranco Conté may publish in the future.

Co-authorship network of co-authors of Pierfranco Conté

This figure shows the co-authorship network connecting the top 25 collaborators of Pierfranco Conté. A scholar is included among the top collaborators of Pierfranco Conté based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierfranco Conté. Pierfranco Conté is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts’ Study 2025 ·Cancers ·Alessandra Buja, Massimo Rugge, (unknown), Manuel Zorzi, Federico Rea, (unknown), Giovanna Scroccaro, Pierfranco Conté, Giulia Pasello, Valentina Guarneri, (unknown)	0
2	A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. 2024 ·Journal of Clinical Oncology ·Pierfranco Conté, Maria Vittoria Dieci, Giancarlo Bisagni, Peter Schmid, Vittoria Fotia, Federico Piacentini, Michelino De Laurentiis, Adolfo Favaretto, Stefano Tamberi, Giulia Bianchi, Claudio Zamagni, Saverio Cinieri, Domenico Corsi, Lucia Del Mastro, Antonella Ferro, Alessandra Gennari, (unknown), Antonino Musolino, Gian Luca De Salvo, Valentina Guarneri	16
3	Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B) 2024 ·ESMO Open ·Guillermo Villacampa, Tomás Pascual, Fara Brasó‐Maristany, Laia Paré, Olga Martínez‐Sáez, Javier Cortés, Eva Ciruelos, Miguel Martín, Pierfranco Conté, Lisa A. Carey, Aranzazu Fernández-Martínez, Nadia Harbeck, Mercedes Marín‐Aguilera, Ana Vivancos, Giuseppe Curigliano, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Aleix Prat, Sara M. Tolaney	7
4	Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 2023 ·Journal of Clinical Oncology ·Hans von der Maase, Steen Werner Hansen, J.T. Roberts, Luigi Dogliotti, T. Oliver, Malcolm J. Moore, I. Bodrogi, Peter Albers, Alexander Knuth, Christian Lippert, Pierre Kerbrat, Pedro Sánchez‐Rovira, Peter Wersäll, Simon Cleall, D. Roychowdhury, (unknown), Carla Visseren‐Grul, Pierfranco Conté	19
5	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer 2020 ·Clinical Cancer Research ·Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, Pierfranco Conté, Véronique Dièras, Nancy U. Lin, (unknown), Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders	144
6	Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 2020 ·JNCI Journal of the National Cancer Institute ·Francesco Schettini, Fabiola Giudici, Mario Giuliano, Massimo Cristofanilli, Grazia Arpino, Lucia Del Mastro, Fabio Puglisi, Sabino De Placido, Ida Paris, Pietro De Placido, Sergio Venturini, M. De Laurentis, Pierfranco Conté, Dejan Juric, Antonio Llombart‐Cussac, Lajos Pusztai, Aleix Prat, Guy Jérusalem, Angelo Di Leo, Daniele Generali	62
7	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology 2020 ·Cancers ·(unknown), Alessandro Dal Maso, Giulia Pasello, (unknown), (unknown), Pierfranco Conté, Laura Evangelista	6
8	Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer breakdown → 2019 ·New England Journal of Medicine ·Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, Pierfranco Conté, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, (unknown), David Mills, Celine Wilke, Samit Hirawat, Dejan Juric	1565
9	Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 2019 ·Journal of Palliative Medicine ·(unknown), (unknown), Maria Vittoria Dieci, Cristina Ghiotto, A. Banzato, Alessandra Bianchi, (unknown), Marta Padovan, Floriana Nappo, (unknown), Federica Miglietta, Eleonora Mioranza, Giulia Zago, L. Corti, Valentina Guarneri, Pierfranco Conté	8
10	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 2019 ·Critical Reviews in Oncology/Hematology ·(unknown), Alessandro Dal Maso, Alessandra Ferro, Laura Bonanno, Pierfranco Conté, Giulia Pasello	17
11	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab 2017 ·Clinical Cancer Research ·Laura Bonanno, Angela De Paoli, Elisabetta Zulato, Giovanni Esposito, Fiorella Calabrese, Adolfo Favaretto, Antonio Santo, Alessandro Del Conte, Marco Chilosi, Francesco Oniga, Gabriella Sozzi, Massimo Moro, Francesco Ciccarese, Giorgia Nardo, Roberta Bertorelle, Cinzia Candiotto, Gian Luca De Salvo, Alberto Amadori, Pierfranco Conté, Stefano Indraccolo	39
12	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation breakdown → 2017 ·New England Journal of Medicine ·Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, Pierfranco Conté	2156
13	Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain 2015 ·Journal of Clinical Oncology ·Elena Bandieri, Marilena Romero, Carla Ripamonti, Fabrizio Artioli, (unknown), Caterina Fanizza, Daniele Santini, Luigi Cavanna, Barbara Melotti, Pierfranco Conté, Fausto Roila, Stefano Cascinu, Éduardo Bruera, Gianni Tognoni, Mario Luppi, (unknown)	96
14	Gene expression profiling in breast cancer: A clinical perspective 2013 ·The Breast ·Grazia Arpino, Daniele Generali, Anna Sapino, Lucia Del Mastro, Antonio Frassoldati, M. De Laurentis, P. Pronzato, Giorgio Mustacchi, Marina Elena Cazzaniga, Sabino De Placido, Pierfranco Conté, (unknown), (unknown), Andrea Antonelli, Mario Martinotti, Fabio Puglisi, Alfredo Berruti, Alberto Bottini, Luigi Dogliotti	57
15	Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy 2010 ·Cancer Research ·Giulia Grisendi, Rita Bussolari, (unknown), István Peták, Valeria Rasini, Elena Veronesi, Giorgio De Santis, Carlotta Spano, (unknown), (unknown), (unknown), Franco Bambi, Antonio Frassoldati, Giulio Rossi, Christian Casali, Uliano Morandi, Edwin M. Horwitz, Paolo Paolucci, Pierfranco Conté, Massimo Dominici	198
16	Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 2009 ·Blood ·Massimo Dominici, Valeria Rasini, Rita Bussolari, Xiaohua Chen, Ted J. Hofmann, Carlotta Spano, (unknown), Elena Veronesi, Filippo Bertoni, Paolo Paolucci, Pierfranco Conté, Edwin M. Horwitz	147
17	Epirubicin/taxane combinations in breast cancer: experience from several Italian trials. 2001 ·PubMed ·Pierfranco Conté, Alessandra Gennari, Valentina Guarneri, Elisabetta Landucci, Sara Donati, B. Salvadori, Carmelo Bengala, (unknown), Editta Baldini	3
18	Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study breakdown → 2000 ·Journal of Clinical Oncology ·Hans von der Maase, Steen Werner Hansen, J.T. Roberts, Luigi Dogliotti, T. Oliver, Malcolm J. Moore, I. Bodrogi, Peter Albers, Alexander Knuth, Christian Lippert, Pierre Kerbrat, Pedro Sánchez‐Rovira, Peter Wersäll, Simon Cleall, D. Roychowdhury, (unknown), Carla Visseren‐Grul, Pierfranco Conté	1678
19	Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte‐colony stimulating factor administered to patients with metastatic breast carcinoma 1998 ·Cancer ·Carmelo Bengala, (unknown), Carmelo Tibaldi, Claudio Favre, Renato Vanacore, Francesco Greco, Alessandro Mazzoni, Mariacristina Menconi, Pierantonio Macchia, Pierfranco Conté	1
20	Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma 1998 ·Cancer ·Carmelo Bengala, (unknown), Carmelo Tibaldi, Claudio Favre, Renato Vanacore, Francesco Greco, Alessandro Mazzoni, Mariacristina Menconi, Pierantonio Macchia, Pierfranco Conté	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact